Fluorodeoxyglucose PET of abdominal and pelvic neoplasms: potential role in oncologic imaging.

Goldberg, Mark A.; Lee, M J; Aj, Fischman; Müeller, Peter R.; Alpert, N.M.; Thrall, J H

doi:10.1148/radiographics.13.5.8210589

Cited by 56 publications

(22 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has previously been reported that some low-grade NHLs show low or no FDG uptake, which could limit the use of 18 F-FDG PET in patients with these lymphoma types [15]. Paone and coworkers suggested that in DLBL patients with BM involvement, BM FDG uptake depends on the balance between small (discordant BM involvement) and large (concordant BM involvement) infiltrating cells [16].…”

Section: F-fdg Pet/ct Findingsmentioning

confidence: 99%

Usefulness of 18F-FDG PET/CT for the Evaluation of Bone Marrow Involvement in Patients with High-Grade Non-Hodgkin’s Lymphoma

Lee

Hwang

Hong

et al. 2012

Nucl Med Mol Imaging

View full text Add to dashboard Cite

Section: F-fdg Pet/ct Findingsmentioning

confidence: 99%

Usefulness of 18F-FDG PET/CT for the Evaluation of Bone Marrow Involvement in Patients with High-Grade Non-Hodgkin’s Lymphoma

Lee

Hwang

Hong

et al. 2012

Nucl Med Mol Imaging

View full text Add to dashboard Cite

“…Recent studies have shown that the uptake of [ 18 F]FDG is increased in many tumor entities compared to normal tissue [10,11]. Effective chemotherapy has been found to reduce the [ 18 F]FDG uptake prior to volumetric changes in morphological imaging techniques such as computed tomography (CT) [12][13][14].…”

Section: Introductionmentioning

confidence: 99%

Diagnostic Value of <sup>18</sup>F-FDG Positron Emission Tomography for Detection and Treatment Control of Malignant Germ Cell Tumors

Tsatalpas¹,

Beuthien‐Baumann

Kropp

et al. 2002

Urol Int

View full text Add to dashboard Cite

Introduction: The role of positron emission tomography (PET) with 2-[¹⁸F]fluoro-2-deoxy-D-glucose ([¹⁸F]FDG) is currently under evaluation in urologic oncology. The aim of the present study was to investigate the use of [¹⁸F]FDG positron emission tomography ([¹⁸F]FDG-PET) in the detection and treatment control of malignant germ cell tumors compared to computed tomography (CT). Materials and Methods: Thirty-two PET studies and CT scans were carried out in 23 patients with histologically proven germ cell tumors (10 seminomas, 12 non-seminomatous germ cell tumors (NSGCT), 1 unclassified serologic recurrent disease) Lugano stage I–III. The scans were done either after initial diagnosis (n = 21) and/or within 3–45 days after chemotherapy was completed (n = 11). PET and CT were validated either by histology (n = 7) or clinical follow-up of 6–11 months after the last PET study has been performed (n = 16). Sensitivity, specificity, accuracy, positive and negative predictive values were determined for PET and CT. Differences between PET and CT for parameters of diagnostic value were evaluated by χ² test. Results: Although not statistically significant, the sensitivity, accuracy and negative predictive value were higher for PET than for CT with respect to the detection of metastatic infradiaphragmatic and supradiaphragmatic lesions after initial diagnosis. The specificity and positive predictive value of PET and CT were comparable. After chemotherapy, PET was found to be significantly superior in specificity and accuracy compared to CT with respect to infradiaphragmatic lesions (p < 0.05). False-positive PET findings in supradiaphragmatic lesions after chemotherapy occurred in the case of inflammatory processes and resulted in a loss of specificity and accuracy compared to CT (p < 0.05). Conclusions: These preliminary results demonstrate [¹⁸F]FDG-PET to be a useful diagnostic tool for the initial staging and treatment control in patients with germ cell tumors. Possible advantages compared to CT, however, are as yet not clearly defined. The possibility of false-positive PET findings due to reactive supradiaphragmatic inflammatory processes early after chemotherapy have to be considered.

show abstract

“…The limitations of 18 F-FDG PET/CT are poor spatial resolution in comparison with other modalities, low uptake in hypometabolic tumors, and false-positive accumulations in inflammatory lesions. [20][21][22] Poor spatial resolution results in very low detection rates for small lesions. In this study, all lesions smaller than 1 cm in greatest diameter occurred in the lungs.…”

Section: Discussionmentioning

confidence: 99%

Usefulness¹⁸F-FDG positron emission tomography/computed tomography for detecting recurrence of hepatocellular carcinoma in posttransplant patients

et al. 2010

View full text Add to dashboard Cite

F-fluoro-2-deoxy-D-glucose (18 F-FDG) positron emission tomography (PET)/computed tomography (CT) has recently been shown to be able to predict a poor outcome after liver transplantation (LT) for patients with hepatocellular carcinoma (HCC). However, there are few reports on the usefulness of PET during follow-up after LT. In this study, we assessed the efficacy of F-FDG PET/ CT during follow-up were included. The accuracy of 18 F-FDG PET/CT was assessed with imaging and histological studies. The most common sites of recurrence were extrahepatic (60%). The most common extrahepatic sites were the lungs and bone (31.3% each). Among 4 patients with intrahepatic recurrence, 1 patient (25%) was positive according to 18 F-FDG PET/CT. The detection rate of 18 F-FDG PET/CT was 92.9% for extrahepatic metastases ! 1 cm and 0% for lesions < 1 cm. The detection rate of 18 F-FDG PET/CT was 100% in bone and the lymph nodes, 60% in the lungs, and 0% in the brain. 18 F-FDG PET/CT identified 2 lesions in bone that were not found in a bone scan. In conclusion, because of its limitations for small lesions, intrahepatic lesions, and brain lesions, 18 F-FDG PET/CT is not suitable as a screening tool after LT. However, 18 F-FDG PET/CT could provide additional information beyond that provided by conventional modalities, and it could contribute to the clinical management of HCC recurrence after LT, especially in patients with extrahepatic recurrence. Liver Transpl 16:767-772,

show abstract

Fluorodeoxyglucose PET of abdominal and pelvic neoplasms: potential role in oncologic imaging.

Cited by 56 publications

References 0 publications

Usefulness of 18F-FDG PET/CT for the Evaluation of Bone Marrow Involvement in Patients with High-Grade Non-Hodgkin’s Lymphoma

Usefulness of 18F-FDG PET/CT for the Evaluation of Bone Marrow Involvement in Patients with High-Grade Non-Hodgkin’s Lymphoma

Diagnostic Value of <sup>18</sup>F-FDG Positron Emission Tomography for Detection and Treatment Control of Malignant Germ Cell Tumors

Usefulness¹⁸F-FDG positron emission tomography/computed tomography for detecting recurrence of hepatocellular carcinoma in posttransplant patients

Contact Info

Product

Resources

About

Fluorodeoxyglucose PET of abdominal and pelvic neoplasms: potential role in oncologic imaging.

Cited by 56 publications

References 0 publications

Usefulness of 18F-FDG PET/CT for the Evaluation of Bone Marrow Involvement in Patients with High-Grade Non-Hodgkin’s Lymphoma

Usefulness of 18F-FDG PET/CT for the Evaluation of Bone Marrow Involvement in Patients with High-Grade Non-Hodgkin’s Lymphoma

Diagnostic Value of <sup>18</sup>F-FDG Positron Emission Tomography for Detection and Treatment Control of Malignant Germ Cell Tumors

Usefulness18F-FDG positron emission tomography/computed tomography for detecting recurrence of hepatocellular carcinoma in posttransplant patients

Contact Info

Product

Resources

About

Usefulness¹⁸F-FDG positron emission tomography/computed tomography for detecting recurrence of hepatocellular carcinoma in posttransplant patients